Make Drug Approval Easier – Econlib
The Challenge of Innovation in the Health Industry
A recent EconTalk podcast featuring cardiologist Eric Topol discussing aging-related health issues sparked an interesting conversation about the challenges of innovation in the health industry.
An important point raised in the discussion was the lack of progress in optimizing nanoparticles and mRNA technology to minimize side effects. Topol highlighted that while advancements have been made in other countries like Japan, the United States is lagging behind in adopting these innovations.
The main factor hindering progress in the U.S. is the stringent regulatory process imposed by the Food and Drug Administration (FDA). Since the 1962 amendment to drug approval laws, companies seeking to introduce new drugs or technologies face a lengthy and costly process of demonstrating both safety and efficacy.
This regulatory burden not only delays the introduction of new and improved treatments but also discourages companies from investing in innovative solutions due to the high costs and risks involved.
One proposed solution to this issue is to streamline the approval process by allowing drugs that have been approved by reputable regulatory bodies in other countries to be automatically approved in the U.S. This would not only accelerate the introduction of new technologies but also promote competition and drive down healthcare costs.
By reducing regulatory barriers and promoting a more flexible and efficient approval process, the healthcare industry can foster greater innovation and provide patients with access to cutting-edge treatments and therapies.
